Core Insights - BioAtla, Inc. reported encouraging clinical outcomes from its Conditionally Active Biologic (CAB) platform, particularly in its Phase 1 dose-escalation study for dual conditionally-binding EpCAM and CD3, with multiple patients showing tumor reduction and tolerating therapy without progression [2][4][5] - The company has restructured its organization to reduce costs and extend its financial runway, focusing on prioritizing patient recruitment for programs expected to yield transformative results [2][10][13] Financial Performance - For Q4 2024, research and development (R&D) expenses were $11.6 million, down from $22.7 million in Q4 2023, attributed to lower clinical development expenses due to program prioritization [10] - General and administrative (G&A) expenses decreased to $4.6 million in Q4 2024 from $5.9 million in Q4 2023, primarily due to lower stock-based compensation and personnel costs [11] - The net loss for Q4 2024 was $14.9 million, a reduction from a net loss of $26.9 million in the same quarter of 2023 [11] - Cash and cash equivalents at year-end 2024 stood at $49 million, down from $111.5 million at the end of 2023, with expectations that cost reductions will extend the runway beyond key clinical readouts in 1H 2026 [13][26] Clinical Program Updates - The Phase 1 dose-escalation study for CAB-EpCAM x CAB-CD3 (BA3182) is ongoing, with data readout expected in mid-2025, and dose expansion data anticipated in 1H 2026 [4][5] - Mecbotamab vedotin (CAB-AXL-ADC) demonstrated a 66% overall survival rate at one year and 58% at two years among patients with mKRAS NSCLC, exceeding standard care benchmarks [4][9] - Ozuriftamab vedotin (CAB-ROR2-ADC) showed promising anti-tumor activity in treatment-refractory metastatic HPV-positive squamous cell carcinoma of the head and neck, with a 45% overall response rate [4][19] Corporate Strategy and Future Outlook - The company is advancing multiple discussions with potential collaborators for its Phase 2 assets while initiating new partnerships [2][6] - BioAtla is focusing on its two internal priority programs and has initiated workforce reductions of over 30% to align resources effectively [10][12] - The management plans to host a conference call to discuss these developments and financial results, indicating a commitment to transparency with stakeholders [14]

Core Insights - BioAtla, Inc. is a clinical-stage biotechnology company focused on developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors [1][3] - The company announced two abstracts accepted for poster presentations at the European Lung Cancer Congress (ELCC) 2025 and the Mayo Clinic Multidisciplinary Head and Neck Cancer Symposium 2025 [1][2] Company Overview - BioAtla operates in San Diego, California, and Beijing, China, through a partnership with BioDuro-Sundia for preclinical development services [3] - The company utilizes proprietary CAB technology to develop novel monoclonal and bispecific antibodies, aiming for selective targeting, greater efficacy, lower toxicity, and cost-efficient manufacturing compared to traditional antibodies [3] - BioAtla holds extensive patent coverage with over 780 active patent matters, including more than 500 issued patents, covering methods of making, screening, and manufacturing CAB product candidates [3] Clinical Development - BioAtla has two first-in-class CAB programs in Phase 2 clinical testing: mecbotamab vedotin (CAB-AXL-ADC) and ozuriftamab vedotin (CAB-ROR2-ADC) [3] - The company is also developing evalstotug, a Phase 2 CAB-CTLA-4 antibody designed to reduce systemic toxicity and enable safer combination therapies with checkpoint inhibitors [3] - The first dual CAB bispecific T-cell engager antibody, BA3182, is currently in Phase 1 development, targeting EpCAM on adenocarcinomas while engaging human CD3 expressing T cells [3]

Core Insights - BioAtla, Inc. is a clinical-stage biotechnology company focused on developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors [1][3] - The company will host a conference call on March 27, 2025, to discuss its financial results for Q4 and the full year ended December 31, 2024 [1][2] Company Overview - BioAtla operates in San Diego, California, and has a partnership in Beijing, China for preclinical development services [3] - The company utilizes proprietary CAB technology to create novel monoclonal and bispecific antibodies, aiming for selective targeting, greater efficacy, lower toxicity, and cost-efficient manufacturing compared to traditional antibodies [3] - BioAtla holds over 780 active patent matters, with more than 500 issued patents, covering methods of making, screening, and manufacturing CAB product candidates [3] Clinical Development - BioAtla has two first-in-class CAB programs in Phase 2 clinical testing: mecbotamab vedotin (CAB-AXL-ADC) and ozuriftamab vedotin (CAB-ROR2-ADC) [3] - The company is also developing evalstotug, a CAB-CTLA-4 antibody designed to reduce systemic toxicity and enable safer combination therapies with checkpoint inhibitors [3] - BA3182, the first dual CAB bispecific T-cell engager antibody, is currently in Phase 1 development, targeting EpCAM on adenocarcinomas [3]

Core Viewpoint - BioAtla, Inc. has announced a registered direct offering of 9,679,158 shares of common stock, aiming to raise approximately $9.2 million to fund its research and development efforts, particularly for its mid-stage clinical programs [1][4]. Group 1: Offering Details - The offering includes warrants to purchase one share of common stock at an exercise price of $1.19 per share, with a combined offering price of $0.9520 per share and warrant [1]. - The closing of the offering is expected to occur on or about December 20, 2024, subject to customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds will be used to fund research and development, including key inflection points for the mid-stage clinical TCell Engager (TCE) and Antibody Drug Conjugate (ADC) programs [4]. - Specific programs mentioned include BA3182 (Phase 1 data expected in 2Q25) and mecbotamab vedotin (Phase 2B data expected in 1H26) [4]. Group 3: Company Overview - BioAtla is a clinical-stage biotechnology company focused on developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors [1][10]. - The company has two first-in-class CAB programs in Phase 2 clinical testing and a dual CAB bispecific T-cell engager antibody in Phase 1 development [10]. - BioAtla holds extensive patent coverage for its CAB technology, with over 780 active patent matters [10].

Core Insights - BioAtla, Inc. presented data indicating improved one-year overall survival (OS) for patients with treatment-refractory non-small cell lung cancer (NSCLC) expressing mutated KRAS (mKRAS) treated with Mecbotamab Vedotin (Mec-V) compared to those with wild-type KRAS (wtKRAS) [1][2] - The one-year OS was reported at 58% for mKRAS patients versus 23% for wtKRAS patients, suggesting Mec-V's potential as a promising treatment option across all KRAS mutation variants [2][3] - A randomized trial of Mec-V in patients with treatment-refractory mKRAS NSCLC is planned for initiation in 2025 based on these findings [2] Company Overview - BioAtla, Inc. is a global clinical-stage biotechnology company focused on developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors [1][4] - The company has two first-in-class CAB programs currently in Phase 2 clinical testing: Mecbotamab Vedotin targeting AXL and ozuriftamab vedotin targeting ROR2 [5] - BioAtla has extensive patent coverage for its CAB technology, with over 780 active patent matters, including more than 500 issued patents [5] Clinical Trial Data - The Phase 2 trial of Mec-V enrolled 78 patients, with 30.7% having mKRAS NSCLC [3] - Among the 21 efficacy-evaluable patients with mKRAS NSCLC, the overall response rate (ORR) was 28.6%, with notable antitumor activity observed across 9 different mKRAS variants [3] - Treatment with Mec-V was well tolerated, showing a manageable safety profile without new safety signals [3] AXL Expression and KRAS Mutation - A strong correlation was confirmed between KRAS mutations and AXL expression, with 70.3% of NSCLC samples harboring any KRAS mutation showing high AXL expression [2][3] - Among the mKRAS G12C variant subset, 81.8% exhibited high AXL expression, reinforcing the relevance of AXL as a therapeutic target [3]

Core Insights - BioAtla, Inc. presented promising data on Mecbotamab Vedotin (Mec-V) for treatment-refractory non-small cell lung cancer (NSCLC) with mutated KRAS (mKRAS), showing a one-year overall survival (OS) of 58% compared to 23% for wild-type KRAS (wtKRAS) patients [1][3][4] Group 1: Clinical Trial Results - The Phase 2 trial of Mec-V included 78 patients, with 30.7% having mKRAS NSCLC [4] - Among patients with mKRAS NSCLC, the median OS was not yet reached, while the median OS for wtKRAS was 8.7 months [4] - The overall response rate (ORR) for mKRAS NSCLC patients was 28.6%, with notable antitumor activity across 9 different mKRAS variants [4] Group 2: Mechanism and Targeting - Mec-V is a conditionally active antibody-drug conjugate targeting AXL, which is highly expressed in mKRAS NSCLC [6][4] - A strong correlation was confirmed between mKRAS mutations and AXL expression, with 70.3% of NSCLC samples harboring KRAS mutations showing high AXL expression [3][4] Group 3: Future Plans - BioAtla plans to initiate a randomized trial of Mec-V in 2025 for patients with treatment-refractory mKRAS NSCLC based on the encouraging findings [3][4] - The company has received Orphan Drug Designation from the FDA for Mec-V in treating soft tissue sarcoma, indicating its potential across multiple solid tumor indications [6]

BioAtla, Inc. (NASDAQ:BCAB) Q3 2024 Earnings Call Transcript November 7, 2024 4:30 AM ET Company Participants Bruce Mackle - LifeSci Advisors, Investor Relations Jay Short - Chairman, Chief Executive Officer and Cofounder Richard Waldron - Chief Financial Officer Eric Sievers - Chief Medical Officer Conference Call Participants Jeet Mukherjee - BTIG Tony Butler - Rodman & Renshaw Yu He - H.C. Wainwright Operator Good day, everyone, and welcome to today's BioAtla Third Quarter 2024 Earnings Call. [Operator I ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value per share BCAB The Nasdaq Global Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to C ...

BIOATLA REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS – Ozuriftamab vedotin (CAB-ROR2-ADC) Phase 2 trial in squamous cell carcinoma of the head and neck (SCCHN) continues to demonstrate durable clinical responses and median overall survival (OS) of approximately 9 months (ongoing) in a heavily pretreated population; actionable feedback received from the U.S. Food and Drug Administration (the "FDA") regarding our proposed pivotal trial in second-line (2L) plus SCCHN – Evalstotug ...

BioAtla, Inc. (NASDAQ: BCAB ) develops innovative cancer treatments with its proprietary Conditionally Active Biologics [CAB] platform. This technology allows for precise targeting of disease tissues while minimizing harm to healthy cells. This is a key benefit that typicalMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, USA, a ...